Nakamura K, Okamoto N, Mizutani S
Department of Virology, National Children's Medical Research Center.
Rinsho Ketsueki. 1994 Sep;35(9):853-61.
Forty cases of Ph1-positive CML patients, who were followed up for a long period, were evaluated for bcr-abl mRNA using RT-PCR. We analyzed the relation of the bcr-abl mRNA subtype to the duration of chronic phase and blast crisis lineage. The mean duration of the chronic phase was 2 years 3 months (2Y3M) in b2-a cases, 1Y11M in b3-a, and 1Y4M in both b2-a and b3-a cases. The myeloid/lymphoid ratio at the blastic phase was 1.0 in b2-a, 0.33 in b3-a, and 2.5 in both mRNA cases. No significant difference was observed in the mean duration of the chronic phase and the frequency of two kinds of blast crisis lineage among different bcr-abl mRNA cases. We also evaluated CML patients in clinical remission after BMT. Bcr-abl mRNA was detectable in 6 of 7 cases (6/7) within 6 months after BMT, all five cases from 6 months to 1 year (1Y), 2/8 at 1Y, 3/7 at 2Y, and 3/7 over 3Y. It suggested the longer time after BMT, the more patients were negative for RT-PCR. In one patient, RT-PCR signal became undetectable at 9Y. This demonstrated that bcr-abl mRNA-positive residual cells could be eradicated long after BMT.
对40例长期随访的Ph1阳性慢性粒细胞白血病（CML）患者，采用逆转录聚合酶链反应（RT-PCR）检测bcr-abl mRNA。分析bcr-abl mRNA亚型与慢性期持续时间及急变期谱系的关系。b2-a型病例慢性期平均持续时间为2年3个月（2Y3M），b3-a型为1年11个月（1Y11M），b2-a和b3-a混合型为1年4个月（1Y4M）。急变期髓系/淋系比例在b2-a型为1.0，b3-a型为0.33，两种mRNA混合型为2.5。不同bcr-abl mRNA病例的慢性期平均持续时间及两种急变期谱系的频率未见显著差异。我们还评估了异基因骨髓移植（BMT）后处于临床缓解期的CML患者。BMT后6个月内，7例中有6例（6/7）可检测到bcr-abl mRNA，6个月至1年（1Y）的5例均能检测到，1Y时8例中有2例可检测到，2Y时7例中有3例可检测到，3年以上7例中有3例可检测到。这表明BMT后时间越长，RT-PCR检测呈阴性的患者越多。1例患者在9年时RT-PCR信号消失。这表明BMT后很长时间仍可清除bcr-abl mRNA阳性残留细胞。
